Interacting Drugs |
Lansoprazole, amoxicillin, and clarithromycin vs CYP2C19 Substrates |
Security Level |
|
Mechanism |
CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates. |
Management |
Monitor therapy |
Lansoprazole, amoxicillin, and clarithromycin vs CYP2C19 Substrates
Post Review about Lansoprazole, amoxicillin, and clarithromycin vs CYP2C19 Substrates Click here to cancel reply.
Other Interactions of Lansoprazole, amoxicillin, and clarithromycin
Other Interactions of CYP2C19 Substrates
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.